Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01223976|
Recruitment Status : Unknown
Verified October 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : October 19, 2010
Last Update Posted : October 19, 2010
|Condition or disease||Intervention/treatment||Phase|
|Tuberculosis Psoriasis||Other: Tuberculin skin test and Quantiferon -TB Gold test||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis|
|Study Start Date :||November 2010|
|Estimated Primary Completion Date :||June 2011|
|Estimated Study Completion Date :||August 2011|
- Other: Tuberculin skin test and Quantiferon -TB Gold test
TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.
QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions.
- The level of agreement between TST and QTF in patients with psoriasis in comparison with controls [ Time Frame: 3 days ]
- Levels of TST in patients with psoriasis in comparison with healthy controls [ Time Frame: 3 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01223976
|Contact: Ori Elkayam, MDemail@example.com|
|Contact: Ayelet Brillfirstname.lastname@example.org|
|Tel Aviv Medical Center||Not yet recruiting|
|Tel Aviv, Israel, 64239|
|Contact: Ori Elkayam, M.D 97236973668 email@example.com|
|Principal Investigator: Ori Elkayam|
|Sub-Investigator: Hagit Mats|